Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.3K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.3K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

455
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
455
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Pulmonary Embolism III: Nursing Management01:27

Pulmonary Embolism III: Nursing Management

618
A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
618
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

360
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
360

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Alirocumab plus cemiplimab in advanced immuno-refractory metastatic non-small cell lung cancer: an ongoing multi-center phase II study.

Future oncology (London, England)·2026
Same author

Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): conventional and distribution-based immune profiling of the tumor microenvironment and peripheral circulation.

Journal for immunotherapy of cancer·2025
Same author

Neoadjuvant, Perioperative, and Adjuvant Immunotherapy in Early-Stage Surgically Resectable Non-Small Cell Lung Cancer: Updates and Future Perspectives.

Cancers·2025
Same author

A Critical Review of Immunomodulation in the Management of Inoperable Stage III NSCLC.

Cancers·2025
Same author

Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysis.

Journal for immunotherapy of cancer·2025
Same author

Sotorasib for the treatment of locally advanced/metastatic non-small cell lung cancer.

Future oncology (London, England)·2024
Same journal

Correction: Jiménez-Sánchez et al. Antioxidant Enzymes Genetic Variants Associated with Urticaria/Angioedema Induced by Cross-Reactive Hypersensitivity to Nonsteroidal Anti-Inflammatory Drugs. <i>Pharmaceuticals</i> 2026, <i>19</i>, 522.

Pharmaceuticals (Basel, Switzerland)·2026
Same journal

Correction: Zhao et al. Multifunctional Gel Films of Marine Polysaccharides Cross-Linked with Poly-Metal Ions for Wound Healing. <i>Pharmaceuticals</i> 2022, <i>15</i>, 750.

Pharmaceuticals (Basel, Switzerland)·2026
Same journal

Intravenous Immunoglobulin Reveals a Novel Protective Mechanism: Targeting the GBP5-Driven Pyroptosis Axis in Experimental Colitis.

Pharmaceuticals (Basel, Switzerland)·2026
Same journal

Icariin Attenuates Renal Injury in Streptozotocin-Induced Diabetic Rats with and Without Adenine-Induced Chronic Kidney Disease.

Pharmaceuticals (Basel, Switzerland)·2026
Same journal

AI-Assisted Identification of a Putative Allosteric Ligand Targeting the CDK4/Cyclin D1 Protein-Protein Interface.

Pharmaceuticals (Basel, Switzerland)·2026
Same journal

Development and Study of Hydrophilic Ointment Compositions with a Dextrin/Polyvinyl Alcohol/Iodine Complex (D/PVA/I).

Pharmaceuticals (Basel, Switzerland)·2026
See all related articles

Related Experiment Video

Updated: Mar 18, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.5K

Heparin: Past, Present, and Future.

Eziafa I Oduah1,2, Robert J Linhardt3, Susan T Sharfstein4

  • 1SUNY Polytechnic Institute, Albany, NY 12203, USA. eoduah@bhs1.org.

Pharmaceuticals (Basel, Switzerland)
|July 8, 2016
PubMed
Summary
This summary is machine-generated.

Developing non-animal-derived heparin is crucial due to contamination risks. Bioengineered heparin offers potential for new therapies beyond anticoagulation, including cancer and inflammation treatments.

Keywords:
Chinese hamster ovary cellsUFHanti-inflammatoryantitumorbioengineeringheparan sulfateheparinheparin-like moleculeslow molecular weight heparin

More Related Videos

Polyelectrolyte Complex for Heparin Binding Domain Osteogenic Growth Factor Delivery
12:27

Polyelectrolyte Complex for Heparin Binding Domain Osteogenic Growth Factor Delivery

Published on: August 22, 2016

8.1K
Through-the-Wall Blood Sampling Method to Minimize Sleep Disruption in Clinical Settings
06:39

Through-the-Wall Blood Sampling Method to Minimize Sleep Disruption in Clinical Settings

Published on: June 13, 2025

577

Related Experiment Videos

Last Updated: Mar 18, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.5K
Polyelectrolyte Complex for Heparin Binding Domain Osteogenic Growth Factor Delivery
12:27

Polyelectrolyte Complex for Heparin Binding Domain Osteogenic Growth Factor Delivery

Published on: August 22, 2016

8.1K
Through-the-Wall Blood Sampling Method to Minimize Sleep Disruption in Clinical Settings
06:39

Through-the-Wall Blood Sampling Method to Minimize Sleep Disruption in Clinical Settings

Published on: June 13, 2025

577

Area of Science:

  • Biotechnology
  • Biochemistry
  • Pharmacology

Background:

  • Heparin, a vital anticoagulant, is currently animal-derived, posing risks of adulteration and contamination.
  • A 2007-2008 crisis highlighted the need for safer, non-animal heparin sources produced under current Good Manufacturing Practices (cGMP).
  • Emerging research suggests heparin possesses antineoplastic, anti-inflammatory, and other therapeutic properties distinct from anticoagulation.

Purpose of the Study:

  • To review strategies for producing bioengineered heparin, addressing limitations of current animal-derived sources.
  • To explore novel therapeutic applications of heparin beyond anticoagulation.
  • To propose methods for creating "designer" heparins and heparan-sulfates with tailored properties.

Main Methods:

  • Review of microbial production systems for heparin.
  • Analysis of mammalian cell-based production strategies.
  • Discussion of chemoenzymatic modification approaches for heparin synthesis.

Main Results:

  • Multiple strategies exist for bioengineered heparin production, including microbial, mammalian cell, and chemoenzymatic methods.
  • These approaches aim to mitigate risks associated with animal-derived heparin.
  • Potential exists for developing "designer" heparins with specific therapeutic functionalities.

Conclusions:

  • Bioengineering offers a promising route to safe, consistent, and potentially more versatile heparin.
  • Further research into bioengineered heparin could unlock new treatments for cancer, inflammation, and infectious diseases.
  • Tailored heparin derivatives may offer enhanced therapeutic profiles and reduced side effects.